CJC-1295 research guide for Rosetta. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
The quest for CJC-1295 in Rosetta almost always leads to the same conclusion: research peptides are distributed through specialist online vendors, not local pharmacies. The upside of this online-only market is that serious vendors compete aggressively on their analytical documentation, giving researchers better verification tools than local retail ever could. Vendors worth sourcing from make readily available batch-matched Certificates of Analysis showing HPLC purity analysis, mass spec identity confirmation, endotoxin levels, and residual solvent results — all for the specific lot you are purchasing. This guide guides Rosetta researchers through that evaluation process and explains how to verify CJC-1295 vendor quality step by step.
Understanding CJC-1295 — Biology & Evidence
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Rosetta comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
Sourcing Research-Grade CJC-1295
The first step for any Rosetta researcher sourcing CJC-1295 is finding vendors with verified community track records — organic rankings are no guide to actual CJC-1295 quality. Endotoxin testing in the COA is non-negotiable for any injectable research use — endotoxins from gram-negative bacterial contamination can trigger severe inflammatory responses even at very low concentrations. For Rosetta researchers evaluating unfamiliar vendors: a modest first purchase to test the product before committing to research quantities is the accepted approach among experienced researchers. Hold lyophilised CJC-1295 at −20°C until ready to use; reconstitute only the volume needed for upcoming use and return unused portion to the freezer.
Order CJC-1295 — ships to Rosetta
COA-verified · International tracking · Research grade
CJC-1295 is sold for research purposes only and is not approved for human therapeutic use by the FDA or equivalent regulatory bodies — all information here is provided for educational purposes. Temperature excursions — even short periods above −20°C — can cause partial degradation without any obvious sign; always use only material shipped with appropriate cold protection. The primary quality-related safety risk in CJC-1295 research is endotoxin from inadequately tested product — a verified endotoxin panel in the batch COA is the direct mitigation for this hazard. For any individual considering CJC-1295 outside a formal research context: seek medical advice first — this compound is not approved for human use and its known risks are not comparable to approved pharmaceuticals.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
